# Ignacio Garrido-Laguna

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 121 papers | 7,479 citations | 147801 31 h-index | 56724 83 g-index |
| 121 all docs | 121 docs citations | 121 times ranked | 12187 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of Gastrointestinal Cancer, 2023, 54, 492-500. | 1.3 | 3 |
| 2 | A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States.. Journal of Clinical Oncology, 2022, 40, 39-39. | 1.6 | 1 |
| 3 | Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 268-275. | 4.9 | 3 |
| 4 | Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 144-150. | 4.9 | 4 |
| 5 | Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. , 2022, 10, e004223. | | 6 |
| 6 | Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Annals of Surgical Oncology, 2021, 28, 663-675. | 1.5 | 8 |
| 7 | The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients.. Journal of Clinical Oncology, 2021, 39, 291-291. | 1.6 | 2 |
| 8 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359. | 4.9 | 758 |
| 9 | Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Annals of Translational Medicine, 2021, 9, 1035-1035. | 1.7 | 9 |
| 10 | Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 2021, 50, 796-802. | 1.1 | 1 |
| 11 | Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 2021, 50, 773-787. | 1.1 | 3 |
| 12 | A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. Oncologist, 2021, 26, e1844-e1853. | 3.7 | 18 |
| 13 | Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research, 2021, 27, 6314-6322. | 7.0 | 22 |
| 14 | Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia, 2021, 23, 859-869. | 5.3 | 6 |
| 15 | Therapeutic Targeting of Autophagy in Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 709-718. | 1.5 | 4 |
| 16 | Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110458. | 3.2 | 7 |
| 17 | Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 478-482. | 4.9 | 21 |
| 18 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 271-282. | 10.7 | 1,034 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature Reviews Clinical Oncology, 2020, 17, 108-123. | 27.6 | 244 |
| 20 | Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587. | 7.0 | 16 |
| 21 | Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Reports, 2020, 32, 107994. | 6.4 | 15 |
| 22 | Metastatic Pancreatic Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 3217-3230. | 1.6 | 151 |
| 23 | O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Annals of Oncology, 2020, 31, 232-233. | 1.2 | 14 |
| 24 | Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repairâ€“Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precision Oncology, 2020, 4, 780-784. | 3.0 | 2 |
| 25 | The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. PLoS ONE, 2020, 15, e0229063. | 2.5 | 6 |
| 26 | The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer Medicine, 2020, 9, 1703-1711. | 2.8 | 12 |
| 27 | NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 806-815. | 4.9 | 310 |
| 28 | Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. Journal of Immunotherapy and Precision Oncology, 2020, 3, 137-139. | 1.4 | 0 |
| 29 | Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist, 2019, 24, 219-228. | 3.7 | 30 |
| 30 | Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). Annals of Oncology, 2019, 30, iv134. | 1.2 | 7 |
| 31 | Prognostic Factors Affecting Overall Survival in Non-metastatic, Primary Squamous Cell Carcinoma of the Pancreas. International Journal of Radiation Oncology Biology Physics, 2019, 103, E31-E32. | 0.8 | 0 |
| 32 | Firstâ€inâ€human, phase I study of PFâ€06647263, an antiâ€EFNA4 calicheamicin antibodyâ€“drug conjugate, in patients with advanced solid tumors. International Journal of Cancer, 2019, 145, 1798-1808. | 5.1 | 34 |
| 33 | Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 2019, 4, e000539. | 4.5 | 3 |
| 34 | Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 355-362. | 1.3 | 30 |
| 35 | Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for firstâ€“line treatment of metastatic colorectal cancer. Investigational New Drugs, 2019, 37, 482-489. | 2.6 | 17 |
| 36 | Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. Journal of Gastrointestinal Surgery, 2019, 23, 1401-1413. | 1.7 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 330-330. | 1.6 | 1 |
| 38 | Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.. Journal of Clinical Oncology, 2019, 37, 69-69. | 1.6 | 1 |
| 39 | Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1109-1133. | 4.9 | 92 |
| 40 | The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 419-419. | 1.6 | 1 |
| 41 | Cancer Immunotherapy in the Immunosuppressed Patients and Its Relevance to Clinical Practice. Journal of Immunotherapy and Precision Oncology, 2019, 2, 127-128. | 1.4 | 1 |
| 42 | NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 359-369. | 4.9 | 675 |
| 43 | Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open, 2018, 3, e000282. | 4.5 | 21 |
| 44 | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncology, 2018, 14, 947-962. | 2.4 | 9 |
| 45 | Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2545-2556. | 1.6 | 204 |
| 46 | Combination immunotherapy and radiation therapy strategies for pancreatic cancerâ€"targeting multiple steps in the cancer immunity cycle. Journal of Gastrointestinal Oncology, 2018, 9, 1014-1026. | 1.4 | 42 |
| 47 | Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precision Oncology, 2018, 2, 1-7. | 3.0 | 32 |
| 48 | Large database utilization in health outcomes research in pancreatic cancer: an update. Journal of Gastrointestinal Oncology, 2018, 9, 996-1004. | 1.4 | 8 |
| 49 | TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunology, Immunotherapy, 2018, 67, 1659-1667. | 4.2 | 152 |
| 50 | (OA44) Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. International Journal of Radiation Oncology Biology Physics, 2018, 101, e18-e19. | 0.8 | 2 |
| 51 | Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 2018, 3, e000386. | 4.5 | 11 |
| 52 | Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer. Cancer Research, 2018, 78, CT124-CT124. | 0.9 | 18 |
| 53 | Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.. Journal of Clinical Oncology, 2018, 36, 4015-4015. | 1.6 | 34 |
| 54 | Association of adjuvant chemotherapy with overall survival in resected pancreatic adenocarcinoma previously treated with neoadjuvant therapy.. Journal of Clinical Oncology, 2018, 36, 404-404. | 1.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.. Journal of Clinical Oncology, 2018, 36, 521-521. | 1.6 | 27 |
| 56 | The effect of adjuvant chemotherapy in patients without local nodal metastases following neoadjuvant chemoradiotherapy and esophagectomy for locally advanced esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 111-111. | 1.6 | 0 |
| 57 | A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, TPS524-TPS524. | 1.6 | 0 |
| 58 | Postoperative chemotherapy in patients who are pN+ following neoadjuvant chemoradiation for locally advanced esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 97-97. | 1.6 | 0 |
| 59 | Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series. Journal of Immunotherapy and Precision Oncology, 2018, 1, 1-6. | 1.4 | 0 |
| 60 | Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 2017, 123, 3816-3824. | 4.1 | 35 |
| 61 | Multi-agent Induction Chemotherapy Followed by Chemoradiation is Associated With Improved Survival Compared to Chemotherapy Alone in Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E193-E194. | 0.8 | 0 |
| 62 | Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2017, 24, 4001-4008. | 1.5 | 20 |
| 63 | Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy, 2017, 9, 797-804. | 2.0 | 30 |
| 64 | Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 175-182. | 0.5 | 2 |
| 65 | A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646. | 2.6 | 24 |
| 66 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2017, 8, 387-404. | 1.4 | 21 |
| 67 | A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.. Journal of Clinical Oncology, 2017, 35, 2511-2511. | 1.6 | 6 |
| 68 | Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.. Journal of Clinical Oncology, 2017, 35, 792-792. | 1.6 | 2 |
| 69 | A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. ACG Case Reports Journal, 2017, 4, e34. | 0.4 | 3 |
| 70 | Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and Therapy, 2016, 9, 75. | 2.0 | 5 |
| 71 | Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547. | 4.1 | 63 |
| 72 | Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clinical Neurology and Neurosurgery, 2016, 149, 11-14. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. Annals of Oncology, 2016, 27, vi367. | 1.2 | 0 |
| 74 | Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.. Journal of Clinical Oncology, 2016, 34, 3020-3020. | 1.6 | 21 |
| 75 | Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, 452-452. | 1.6 | 14 |
| 76 | Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531. | 1.8 | 44 |
| 77 | Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nature Reviews Clinical Oncology, 2015, 12, 319-334. | 27.6 | 489 |
| 78 | First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2520-2520. | 1.6 | 4 |
| 79 | N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience, 2015, 2, 285-293. | 2.2 | 4 |
| 80 | Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002 through 2012.. Journal of Clinical Oncology, 2015, 33, 687-687. | 1.6 | 0 |
| 81 | Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012.. Journal of Clinical Oncology, 2015, 33, 311-311. | 1.6 | 0 |
| 82 | Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy.. Journal of Clinical Oncology, 2015, 33, 1526-1526. | 1.6 | 0 |
| 83 | Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. Journal of Clinical Oncology, 2015, 33, 2584-2584. | 1.6 | 0 |
| 84 | Abstract B93: A data base of N of 1 case reports from pancreatic cancer patients enrolled in First-in-man studies 2002 through 2012. , 2015, , . | | 0 |
| 85 | Abstract LB-176: Identification of mutations in histone modification genes in Hodgkin lymphoma. , 2015, , . | | 0 |
| 86 | Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discovery Medicine, 2015, 19, 101-8. | 0.5 | 0 |
| 87 | Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discovery Medicine, 2015, 19, 109-16. | 0.5 | 13 |
| 88 | Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 2014, 120, 2164-2173. | 4.1 | 27 |
| 89 | Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-Based Study in Utah. Clinical Gastroenterology and Hepatology, 2014, 12, 2078-2084.e2. | 4.4 | 42 |
| 90 | A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. Journal of Clinical Oncology, 2014, 32, 2517-2517. | 1.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 2014, 1, 614-623. | 2.2 | 26 |
| 92 | Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS4596-TPS4596. | 1.6 | 0 |
| 93 | Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discovery Medicine, 2014, 18, 323-30. | 0.5 | 6 |
| 94 | Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discovery Medicine, 2014, 18, 331-9. | 0.5 | 8 |
| 95 | A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 1257-1264. | 2.6 | 59 |
| 96 | Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood, 2013, 122, 3048-3048. | 1.4 | 1 |
| 97 | Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity?. Journal of Clinical Oncology, 2012, 30, 892-893. | 1.6 | 2 |
| 98 | Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. Clinical Colorectal Cancer, 2012, 11, 297-303. | 2.3 | 6 |
| 99 | PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology, 2012, 30, 777-782. | 1.6 | 414 |
| 100 | Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer, 2012, 118, 1422-1428. | 4.1 | 88 |
| 101 | KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. PLoS ONE, 2012, 7, e38033. | 2.5 | 44 |
| 102 | PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget, 2012, 3, 1566-1575. | 1.8 | 79 |
| 103 | Outcomes of Patients with Advanced Nonâ€Small Cell Lung Cancer Treated in a Phase I Clinic. Oncologist, 2011, 16, 327-335. | 3.7 | 8 |
| 104 | The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology, 2011, 8, 562-566. | 27.6 | 17 |
| 105 | PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769. | 2.5 | 174 |
| 106 | Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1601-1612. | 1.1 | 127 |
| 107 | PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics, 2011, 10, 558-565. | 4.1 | 311 |
| 108 | Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. Clinical Cancer Research, 2011, 17, 5793-5800. | 7.0 | 204 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology and Therapy, 2011, 12, 598-609. | 3.4 | 103 |
| 110 | A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Molecular Cancer Therapeutics, 2011, 10, 1311-1316. | 4.1 | 354 |
| 111 | Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. Molecular Cancer Therapeutics, 2011, 10, 3-8. | 4.1 | 238 |
| 112 | Abstract 2264: K-ras mutations in colorectal cancer may predict a pattern of organ-specific metastasis. , 2011, , . | | 0 |
| 113 | Abstract 1279: Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. , 2011, , . | | 0 |
| 114 | Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. British Journal of Cancer, 2010, 103, 649-655. | 6.4 | 65 |
| 115 | Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. Journal of Clinical Oncology, 2010, 28, e633-e636. | 1.6 | 77 |
| 116 | Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administrationâ€“Approved Treatment. Clinical Cancer Research, 2010, 16, 4031-4037. | 7.0 | 15 |
| 117 | Abstract 2773: Clinical outcomes of patients with head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. , 2010, , . | | 0 |
| 118 | Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clinical and Translational Oncology, 2009, 11, 183-185. | 2.4 | 2 |
| 119 | New scaffolds for the design of selective estrogen receptor modulators. Organic and Biomolecular Chemistry, 2008, 6, 3486. | 2.8 | 24 |
| 120 | MRI Evaluation of Breast Cancer. New England Journal of Medicine, 2007, 357, 191-193. | 27.0 | 2 |
| 121 | Is There Any Reason to Delay Introduction of Tumor Necrosis Factor in the Management of In-Transit Metastasis of Unresectable Melanoma?. Journal of Clinical Oncology, 2007, 25, 1149-1149. | 1.6 | 4 |